Poland· PL-100192746
Soliris
A eculizumab product containing eculizumabum, registered in Poland by Alexion Europe SAS. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Eculizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AJ01 (eculizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Eculizumab · ATC L04AJ01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Eculizumabum
- Manufacturer
- Alexion Europe SAS
- Country
- Poland (PL)
- ATC code
- L04AJ01
- ATC class
- Eculizumab
- Defined daily dose
- 64 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990643776
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for eculizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eculizumab · interactions on record
2 records
Same medicine, other countries
Eculizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBKEMVAmgen Inc
- IrelandBEKEMV 300 mg Concentrate for solution for infusionAmgen Technology (Ireland) Unlimited Company
- IcelandBekemvAmgen Technology (Ireland) UC*
- NetherlandsBEKEMV 300 mg concentraat voor oplossing voor infusieAmgen Europe B.V.
- NorwayBekemvAmgen Technology Ireland
- SwedenBEKEMV 300 mg Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- CzechiaBEKEMVAmgen Europe B.V., Breda
- SpainBEKEMV 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Technology (Ireland) Unlimited Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bekemv, Soliris
- Liechtenstein · Soliris
- Norway · Bekemv, Soliris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/24318256-4aca-44a1-b060-65a870a8d0e4 GET /v1/drugs/24318256-4aca-44a1-b060-65a870a8d0e4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "300 mg (10 mg/ml)",
"packaging": "05909990643776 ¦ Rpz ¦ EU/1/07/393/001 ¦ 43136\n1 fiol. 30 ml",
"substance": "Eculizumabum 10 mg/ml",
"common_name": "Eculizumabum",
"pl_product_id": "100192746",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about eculizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.